The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB.
Lou S, Cao Z, Chi W, Wang X, Feng M, Lin L, Ding Y, Liu K, Qu L, Zhao G, Bao S, Wang H.
Lou S, et al. Among authors: wang x, wang h.
Front Pharmacol. 2023 Apr 24;14:1164309. doi: 10.3389/fphar.2023.1164309. eCollection 2023.
Front Pharmacol. 2023.
PMID: 37168999
Free PMC article.